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Vitamin D is a membrane antioxidant: hus Vitamin D 3 (cholecalciferol) and its active metabolite 1,25-dihydroxycholecalciferol and also Vitamin 
D 2 (ergocalciferol) and 7-dehydrocholesterol (pro-Vitamin D3) all inhibited iron-dependent liposomal lipid peroxidation. Cholecalciferol, 1 25- 
dihydroxycholecalciferol andergocalciferol were all of similar effectiveness as inhibitors of lipid peroxidation but were less effective than 7- 
dehydrocholesterol; thiswas a better inhibitor of lipid peroxidation than cholesterol, though not ergosterol. The structural basis for the antioxidant 
ability of these Vitamin D compounds i considered in terms of their molecular elationship to cholesterol and ergosterol. Furthermore, the 
antioxidant ability of Vitamin D is compared to that of the anticancer d ug tamoxifen and its 4-hydroxy metabolite (structural mimics of cholesterol) 
and discussed in relation to the anticancer action of this vitamin. 
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1. INTRODUCTION 
Vitamin D, which includes Vitamin D 3 (cholecalci- 
ferol) and Vitamin D 2 (ergocalciferol), is a lipid soluble 
vitamin, which is metabolized to the hormonally active 
1,25(OH)2 derivative of cholecalciferol that has many 
biological effects including control of calcium and phos- 
phorus metabolism [1]. There may, however, be other 
important biological effects of Vitamin D and although 
considerable effort has been put into studying the anti- 
oxidant action of Vitamin E (including ~-tocopherol), 
which protects membranes [2,3] and LDL (low density 
lipoprotein) [4-6] against oxidative damage, the antiox- 
idant potential of Vitamin D has not been investigated. 
We have reported previously that the anticancer drug 
tamoxifen, which is widely used in the treatment, and 
recently in prevention, of breast cancer [7-11], inhibits 
lipid peroxidation in a range of systems [12 15] and 
protects human LDL against oxidative damage [16]. 
Tamoxifen apparently acts as a membrane antioxidant 
by structural mimicry of cholesterol (and ergosterol) 
thus enabling it to act in a similar way to stabilise the 
membrane against lipid peroxidation [13,14,17,18]. It is 
interesting, therefore, that Vitamin D, its active metab- 
olite and also synthetic analogues have been reported to 
have anticancer activity [19-24]. Cholecalciferol, its me- 
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tabolite 1,25-dihydroxycholecalciferol and 7-dehydro- 
cholesterol are derived from and structurally related to 
cholesterol, whereas ergosterol is the parent compound 
of ergocalciferol and this led us to investigate their anti- 
oxidant abilities. The structures of these compounds are 
shown in Fig. 1. 
2. MATERIALS AND METHODS 
2.1. Preparation of liposomes 
Ox-brain phospholipid liposomes were prepared as described previ- 
ously [13,25]. Liposomes were also prepared with and without the 
introduction of the compounds shown in Fig. 1., as described for 
cholesterol, ergosterol and tamoxifen [13,14,17,25]. Ox-brain phos- 
pholipid, Vitamin D 3 (cholecalciferol), Vitamin D2 (ergocalciferol) and 
7-dehydrocholesterol were purchased from Sigma. 1,25-Dihydroxy- 
cholecalciferol was a kind gift grom Dr. Lise Binderup, Leo Pharma- 
ceutical Products Ltd., Ballerup, Denmark. 
2.2. Peroxidation of liposomes 
Reaction mixtures (final volume 1.0 ml) contained liposomes (0.1 
ml), phosphate-buffered saline pH 7.4 (0.5 ml), water (0.2 ml) and 5 
/11 of ethanol or test compound issolved in ethanol, except in the case 
of liposomes already containing introduced compounds. Peroxidation 
was started by adding freshly prepared aqueous solutions of FeC13 (0.1 
ml) and ascorbate (0.1 ml) to give a final concentration f 100 ¢tM of 
each. Incubations were carried out at 37°C for 20 min. At the end of 
the incubation 100¢tl of a 0.2% (w/v) stock solution of BHT (butylated 
hydroxytoluene) in ethanol was added to suppress any further perox- 
idation during the TBA assay itself. The extent of lipid peroxidation 
was measured by the formation of thiobarbituric acid-reactive sub- 
stances (TBARS) as described in [26]. HCI (0.5 ml of 25% v/v) was 
added to each reaction mixture, followed by 0.5 ml of thiobarbituric 
acid solution (1% w/v in 50 mM sodium hydroxide). After heating at 
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Fig. 1. Structures ofVitamin D compounds, tamoxifen and membrane sterols. Structural relationship ofcholecalciferol, 1,25-dihydroxycholecal- 
ciferol and 7-dehydrocholesterol to cholesterol and of ergocalciferol t  ergosterol. 
80°C for 30 min the chromogen was extracted with 2 ml of butan-l-ol 
and the A532 of the upper (organic) layer was measured. 
3. RESULTS 
When added to preformed liposomes, ergocalciferol, 
cholecalciferol, 1,25-dihydroxycholecalciferol and7-de- 
hydrocholesterol each dissolved in ethanol had no effect 
on iron-dependent lipid peroxidation (see Table I), as 
found previously for cholesterol and ergosterol [13,14]. 
However, the introduction of cholesterol or ergosterol 
into ox-brain phospholipid liposomes during their prep- 
aration inhibited iron-dependent lipid peroxidation ap- 
parently by membrane stabilization [13,17,18] and we 
therefore studied the effect of similarly introducing 
cholecalciferol, 1,25-dihydroxycholecalciferol, ergocal- 
ciferol or 7-dehydrocholesterol. Fig. 2 shows that over 
the concentration range tested (up to 1 mM expressed 
as final concentration in the reaction mixture; com- 
pound:phospholipid ratio of 2.6 x 10 ~) ergocalciferol, 
cholecalciferol and 1,25-dihydroxycholecalciferol inhib- 
ited lipid peroxidation but were less effective inhibitors 
than 7-dehydrocholesterol. This inhibitory action was 
expressed as the ICs0 values (see Table I) derived for the 
compounds tested and compared to those previously 
obtained for cholesterol, ergosterol, tamoxifen and 4- 
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Table I
ICs0 values for the inhibition of liposomal lipid peroxidation by chole- 
calciferol, ergocalciferol, 7-dehydrocholesterol, tamoxifen, 4-hy- 
droxytamoxifen, rgosterol and cholesterol 
Compound/Drug Liposomal systems 
Final concentration in reaction 
mixture 
(tiM) (mM) 
Added to Introduced into 
preformed during 
preparation 
Cholesterol N.R.* 0.72" 
7-Dehydrocholesterol N.R. 0.34 
Cholecalciferol N.R. 1.0 
1,25-Dihydroxycholecalciferol N.R. 1.0 
Ergosterol N.R.* 0.054" 
Ergocalciferol N.R. 1.0 
Tamoxifen 63* 0.050* 
4-Hydroxytamoxifen 9* 0.0036* 
N.R. = not reached, i.e. inhibition by the compound oes not reach 
50% and in the above xamples the compounds o not in fact inhibit 
lipid peroxidation i the system indicated. *Data are quoted from 
reference [13]. Values are deduced from the graphs hown in Fig. 2 in 
which each point represents the mean _+ S.D. of 3 5 separate assays. 
ergosterol probably because it has the cholesterol-type 
side chain. In cholecalciferol (also 1,25-dihydroxychole- 
calciferol) and ergocalciferol, ring-B of the sterol nu- 
cleus has opened, thus reducing the potential for inter- 
action with fatty acid side chains and resulting in 
decreased antioxidant ability compared to cholesterol 
and ergosterol, respectively. It is of interest hat the two 
extra hydroxyl groups of 1,25-dihydroxycholecalciferol 
compared to cholecalciferol confer no extra antioxidant 
advantage on the metabolite compared to the parent 
compound. Cholecalciferol and ergocalciferol differ 
only in that they have the same side chains as choles- 
terol and ergosterol, respectively, but they are equally 
effective as inhibitors of lipid peroxidation and it can be 
postulated that while the more hydrophobic ergosterol- 
type side chain may aid incorporation into the lipo- 
somal bilayer in the optimal orientation for interaction 
of the sterol rings (particularly ring B) with the phos- 
pholipid side chains, it is the more planar ergosterol- 
type ring-B that is required for increased inhibition of 
lipid peroxidation through increased interaction with 
phospholipid fatty acid side chains. 
Cholecalciferol, 1,25-dihydroxycholecalciferol, ergo- 
calciferol and 7-dehydrocholesterol are likely to act as 
membrane antioxidants by stabilizing the membrane 
against lipid peroxidation via an interaction between 
their hydrophobic rings (although cholecalciferol, 1,25- 
hydroxytamoxifen [13,17,18]. Table I shows that the 
concentration of 7-dehydrocholesterol equired to in- 
hibit lipid peroxidation by 50% was approximately 2-
fold less than for cholesterol. In contrast he ICs0 values 
for cholecalciferol, 1,25-dihydroxycholecalciferol and 
ergocalciferol were 1.4 higher than for cholesterol. The 
ICs0 values of ergosterol and tamoxifen were approxi- 
mately 15-fold less than for cholesterol and that for 
4-hydroxytamoxifen was 200-fold less. The ICs0 value 
of ergocalciferol was 19-fold more than that of ergos- 
terol. 
4. DISCUSSION 
Cholecalciferol (Vitamin D3), its active metabolite 
1,25-dihydroxycholecalciferol and ergocalciferol (Vita- 
min D2) were found to be membrane antioxidants in this 
study, but were not as effective as cholesterol or ergos- 
terol as inhibitors of iron-dependent lipid peroxidation 
when introduced into phospholipid liposomes (see 
Table I). 7-Dehydrocholesterol was twice as effective as 
cholesterol as an inhibitor of lipid peroxidation and its 
structure (see Fig. 1) shows it to have the ergosterol-type 
ring B: an extra double bond compared to cholesterol 
makes it more planar and thus potentially increasing 
interactions with phospholipid fatty acid side chains 
and indeed ergosterol is a more effective membrane 
antioxidant than cholesterol. However, 7-dehydro- 
cholesterol is not as good a membrane antioxidant as 
1°° I 
90 
80 
7O 
6o 
o~ 
a. 
50 
= 30 
20 
10 
0 
0 .25  0 .5  0.75 1..O 
COMPOUND CONCENTRATION (mM) 
Fig. 52. Inhibition of lipid peroxidation by thc compounds, (m) chole- 
calcifcrol, ([]) 1,25-dihyroxycholecalciferok (o) ergocalcifcrol and (4) 
7-dehydrocholcstcrol, each introduced separately into liposomes dur- 
ing their preparation. Results are mean + S. D., n = 3 5. 
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dihydroxycholecalci ferol  and ergocalciferol have lost 
ring B) and the saturated, monounsaturated and poly- 
unsaturated residues of  the phosphol ip id fatty acid side 
chains, which decreases membrane fluidity as proposed 
previously for cholesterol, ergosterol and tamoxifen 
[13,14,17,18]. Indeed decreased membrane fluidity in 
cancer cells treated with tamoxifen has been reported 
[27]. 
Cholecalciferol, 1,25-dihydroxycholecalciferol,  ergo- 
calciferol and 7-dehydrocholesterol  were all much less 
effective than the anticancer drug tamoxifen and its 
4-hydroxy metabol i te as inhibitors of  l ipid peroxidat ion 
and did not have any effect on peroxidat ion when added 
in ethanol to preformed l iposomes instead of  being in- 
troduced into the l iposomes; a finding reported previ- 
ously for cholesterol and ergosterol [13,14]. This is in 
contrast to tamoxifen and 4-hydroxytamoxifen,  which 
are both potent inhibitors of  l ipid peroxidat ion under 
these condit ions [13,14]. This difference may reflect the 
ease with which this anticancer drug and its 4-hydroxy 
metabol i te are able to enter l iposomes and natural  
membranes. 
The 1,25(OH)2 metabol i te (hormonal  form) is recog- 
nised to be the active form of  Vitamin D for calcium and 
phosphorus metabol ism in the human body and we 
have shown in this study that it has an ant ioxidant 
ability, which may be of  importance in protect ing the 
membranes of  normal  cells against free radical- induced 
oxidative damage as it is possible that these highly lipo- 
philic compounds may accumulate in membranes to 
achieve the concentrat ions found to inhibit l ipid perox- 
idation in this study. Furthermore,  by decreasing mem- 
brane fluidity by the membrane interaction that is 
thought o lead to the observed inhibit ion of  l ipid perox- 
idation, Vitamin D could help inhibit the growth of 
cancer cells (especially metastat ic ells), which often 
have increased membrane fluidity compared to normal  
cells [28]. In this connection, Vitamin D is considered 
to be protective against colon cancer [19], Vitamin D 
metabol ites have been reported to inhibit the growth of  
colon cancer cells in culture [21] and synthetic Vitamin 
D analogues appear to have antiprol i ferative effects on 
breast cancer cells in culture [23,24]. Furthermore,  Vita- 
min D3 is formed in humans by the action of  sunlight 
on skin, and thus its ant ioxidant abil ity (and that of  its 
precursor in skin, 7-dehydrocholesterol)  should help 
protect the cells in which it is formed against he aging 
and carcinogenic effects of  UV (ultra violet) l ight caused 
in part by peroxidat ion of  cell membranes.  
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